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Condensation of 7-hydroxy-1,2,2,4-tetramethylhydroquinoline-6-carbaldehydes with 
various hetaryl-substituted -oxo esters aff orded a series of hybrid hydro-6,8,8,9-tetramethyl-
2H-pyrano[3,2-g]quinolin-2-ones. A number of these compounds exhibited relatively high 
inhibitory activity against blood coagulation factors Xa and XIa. 
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It is known that existing antithrombotic drugs can cause 
uncontrolled bleeding, therefore, researchers face an issue 
related to the development of new inhibitors of blood 
coagulation factors that do not have this disadvantage. At 
present, there are developed and introduced into clinical 
practice1—3 direct inhibitors of blood coagulation enzymes, 
namely, the serine protease factor Xa (FXa), one of the 
key components of thrombus formation.4—7 The developed 
inhibitors of blood coagulation factor XIa (FXIa) are 
undergoing laboratory and clinical trials.8—14 However, 
due to the presence of structurally similar binding sites for 
serine protease factor and thrombin,15,16 the search for 
new selective inhibitors of FXa and FXIa is an actual 
problem. 
For a long time, coumarin derivatives, being the vitamin 
K antagonists, were the only oral anticoagulants. At pres-
ent, a number of coumarin derivatives have been identifi ed 
as exhibiting high inhibitory activity against FXa and 
FXIa.14,17—20 In addition, it was found that derivatives of 
dihydro-21 and tetrahydroquinolines9,10,18,22—23 exhibit 
similar biological activity. 
In the framework of a rational and effi  cient design of 
biologically active compounds, researchers widely use the 
method of molecular hybridization, which is based on the 
combination of several pharmacophore fragments in one 
molecule.24—32 The implementation of such an approach 
in order to search for new highly effi  cient inhibitors of 
blood coagulation factors Xa and XIa based on the hybrid-
ization of hydroquinoline (A) and coumarin (B) rings seems 
to be very promising. 2H-Pyranо[3,2-g]quinolinones 
exemplify this type of hybrid molecules. 
2H-Pyranо[3,2-g]quinolinones 
The purpose of the present work was to obtain new 
substituted pyranо[3,2-g]quinolin-2-one systems with 
various degrees of hydrogenation and to study their in-
hibitory activity against FXa and FXIa.
It is known that Knoevenagel condensation of salicylic 
aldehyde derivatives with methylene active carbonyl com-
pounds leads to coumarins (2H-chromen-2-ones).33—36 
We found that the condensation of 7-hydroxy-1,2,2,4-
tetramethylhydroquinoline-6-carbaldehydes 1 and 2 with 
methyl 2-R-4-methyl-5-pyrimidine-3-oxopropanoates 
3a—e under the conditions we described earlier37 gives 
8,9-dihydro-2H-pyranо[3,2-g]quinolin-2-ones 4a—c and 
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6,7,8,9-tetrahydro-2H-pyranо[3,2-g]quinolin-2-ones 5a—e 
in fairly high yields (70—93%) (Scheme 1). 
Scheme 1 
 =  (1, 4a—e),  (2, 5a—e)
R = Ph (3a, 5a),  (3b, 4a, 5b),  (3c, 5c), 
 (3d, 4b, 5b),  (3e, 4c, 5e)
Reagents and conditions: EtOH, piperidine, refl ux, 2 h. 
A plausible route of this reaction is shown in Scheme 2. 
The dehydration of the Knoevenagel adducts A formed 
from aldehydes 1 or 2 and keto esters 3 leads to arylidene 
derivatives B, the intramolecular cyclization of which gives 
the fi nal products 4 and 5. 
In order to expand the combinatorial library of 2H-pyr-
anо[3,2-g]quinolinones, we involved 4-hetarylthioaceto-
acetic esters 6a,b in the reaction described above. It was 
found that the condensation of hydroxycarbaldehydes 1 
and 2 with esters 6a,b proceeds smoothly in refl uxing 
ethanol in the presence of piperidine and leads to hetaryl-
thio-8,9-dihydro-2H-pyrano[3,2-g]quinolin-2-ones 7a,b 
and hetarylthio-6,7,8,9-tetrahydro-2H-pyrano [3,2-g]-
quinolin-2-ones 8a,b (Scheme 3). Possible side condensation 
of the carbonyl component with the CH-active mercapto-
methylene group did not occur, and the target products 
7a,b and 8a,b were isolated in high yields (79—84%). 
All the synthesized compounds are chromatograph-
ically pure crystalline substances identifi ed by 1H and 
13C NMR spectroscopy and high-resolution mass spectro-
metry. 
The 1H NMR spectra of compounds 4a—с, 5а—е, 
7a,b, and 8a,b, in contrast to the spectra of the starting 
hydroxyquinolinecarbaldehydes 1 and 2, do not exhibit 
signals for the protons of the hydroxy and aldehyde groups. 
Their spectra exhibit signals for the aromatic protons of 
the tricyclic framework in the regions of δ 6.40—6.43 
(Н(10)), 7.38—7.43 (Н(5)), and 8.23—8.52 (Н(4)). The 
signals for the protons H(7) of 8,9-dihydro derivatives 
4a—с and 7a,b are observed as singlets in the region of 
δ 5.48—5.51. In the case of 6,7,8,9-tetrahydro derivatives 
5а—е and 8a,b, the two protons at position 7 (protons A 
and M) and the proton in position 6 (proton X) form 
a three-spin system AMX, with the proton X being addi-
tionally coupled with the protons of the methyl group at 
position 6 of the tricyclic system. The signals for the pro-
tons A of the AMX system are observed in the region of 
Scheme 2 
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δ 1.39—1.41 as triplets (JAM = JAX = 13.0—13.2 Hz) with 
an integral intensity of 1 H. The signals for protons M are 
found at about  δ 1.87 as doublets of doublets (JAM = 
= 13.0—13.2 Hz, JMX = 3.9—4.0 Hz) with an integral 
intensity of 1 H. The protons X resonate at about δ 2.77 
as a poorly resolved septet with an integral intensity of 
1 H; it was impossible in this case to correctly determine 
the spin-spin coupling constants. In the 13C NMR spectra 
of the synthesized compounds, the signals for the carbon 
atoms of the keto group at position 3 of the tricyclic system 
are observed at δ 189—190. 
We carried out preliminary in vitro screening of com-
pounds 4a—c, 5a—e, 7a,b, and 8a,b in order to identify 
the lead compounds and determine their relative inhibitory 
activity against factors Xa and XIa. A reference drug was the 
clinically used oral anticoagulant rivaroxaban, which selec-
tively inhibits factor Xa and has almost no eff ect on factor 
XIa. It was found that compounds 5a and 5c containing 
a phenyl and a piperidine substituent in the pyr imidine ring 
have the greatest inhibitory eff ect on factors Xa and XIa. 
Compounds 4a and 7a moderately inhibited factor XIa 
and slightly inhibited factor Xa (Table 1). Compounds 
4b,c and 7b  slightly activated factors Xa and XIa. 
The obtained results form the basis for further studies 
of the possibilities of the molecular hybridization method 
in order to search for highly effi  cient and selective in-
hibitors of blood coagulation factors among hydroquino-
line derivatives. 
Experimental 
1H and 13C NMR spectra were recorded on an Agilent 
MR 400+ spectrometer (400 and 100 MHz, respectively) in 
DMSO-d6 under normal conditions. High-resolution electro-
spray ionization (ESI) mass spectra were obtained on an Agilent 
Technologies 1260 infi nity instrument with an Agilent 6230 TOF 
LC/MS time-of-fl ight mass detector in the positive ion mode 
(the nebulizer gas (N2) pressure 20 psi, the drying gas fl ow rate 
6 mL min–1, the gas temperature 325 C; the capillary voltage 
4.0 kV, the fragmentator voltage +191 V, the skimmer voltage 
+66 V, the OctRF parameter 750 V; the mass detection range 
50—2000 Da; a Poroshell 120 EC-C18 column (4.6×50 mm, 
2.7 μm), a gradient elution with a mixture of acetonitrile—water 
containing 0.1% of formic acid (the MeCN gradient from 60% 
to 98% over 3 min, the eluent fl ow rate 0.4 mL  min–1)). The 
results were processed using the MassHunter Workstation/Data 
Acquisition V.06.00 software. Melting points were measured 
using a Stuart SMP30 apparatus. Reaction progress, purity of the 
starting compounds and products, as well as the qualitative 
analysis of the reaction mixtures, were monitored by TLC on 
Merck TLC Silica gel 60 F254 plates (eluents chloroform, 
methanol, and their mixtures in various ratios). The spots of 
compounds were visualized in UV light or iodine vapors. 
7-Hydroxy-1,2,2,4-tetramethylhydroquinoline-6-carb ald-
ehydes 1 and 2 were obtained according to the procedures de-
scribed in the works.37,38 The starting methyl 2-R-4-methyl-5-
pyrimidine-3-oxopropionates 3a—e and 4-hetaryl thio acetо acetic 
esters 6a,b were purchased from Alinda Chemical Ltd. 
Synthesis of 3-(2-R-pyrimidine-5-carbonyl)-6,8,8,9-tetra-
methyl-2H-pyranо[3,2-g]quinolin-2-ones (4a—c, 5a—e, 7a,b, 
and 8a,b) (general procedure). A mixture of carbaldehyde 1 or 2 
(0.002 mol), the corresponding ester 3a—e or 6a,b (0.002 mol), 
ethanol (15 mL), and two-three drops of piperidine was refl uxed 
for 2 h. The precipitate formed upon cooling the reaction mixture 
was collected by fi ltration and recrystallized from a mixture of 
EtOH—DMF. 
Scheme 3
 =  (1, 7a,b),  (2, 8a,b)
6—8: R =  (a),  (b)
Reagents and conditions: EtOH, piperidine, refl ux, 2 h. 
Table 1. Inhibitory activity of compounds 4a—c, 5a—e, 7a,b, 
8a,b and rivaroxaban against blood coagulation factors Xa 
and XIa 















* The control sample did not contain the test compounds. 
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3-[4-Methyl-2-(pyrrolidin-1-yl)pyrimidine-5-carbonyl]-
6,8,8,9- tetra methyl-8,9-dihydro-2H-pyranо[3,2-g]quinolin-2-
one (4a). The yield was 0.74 g (83%), m.p. 178—179 С. 1H NMR, 
: 1.36 (s, 6 H, С(8)(СН3)2); 1.82—1.91 (m, 7 H, 2 NCH2CH2 
of pyrrolidine, C(6)СН3); 2.42 (s, 3 H, N(9)CH3); 2.90 (s, 3 Н, 
C(4´)СН3); 3.53 (br.s, 4 H, 2 NCH2 of pyrrol idine); 5.48 (s, 1 H, 
H(7)); 6.40 (s, 1 H, H(10)); 7.38 (s, 1 H, H(5)); 8.23 (s, 1 H, 
H(4)); 8.39 (s, 1 H, H(2´)). 13C NMR, : 18.6; 24.3; 25.3; 29.1; 
29.1; 47.0; 58.4; 95.9; 108.1; 118.0; 120.0; 120.2; 124.4; 125.7; 
130.6; 148.2; 150.9; 158.5; 159.2; 159.6; 160.8; 168.0; 189.9. MS, 




olin-2-one (4b). The yield was 0.69 g (71%), m.p. 193—194 С. 
1H NMR, : 1.01 (t, 3 Н, СН2СН3, J = 7.1 Hz); 1.35 (s, 6 H, 
С(8)(СН3)2); 1.93 (s, 3 Н, C(6)СН3); 2.35 (q, 2 Н, СН2СН3, 
J = 7.1 Hz); 2.38—2.42 (m, 7 H, 2 NCH2CH2NH, N(9)CH3); 
2.90 (s, 3 Н, C(4´)СН3); 3.81 (br.s, 4 H, 2 NCH2CH2NH); 
5.48 (s, 1 H, H(7)); 6.40 (s, 1 H, H(10)); 7.38 (s, 1 H, H(5)); 
8.25 (s, 1 H, H(4)); 8.40 (s, 1 H, H(2´)). 13C NMR, : 12.4; 
18.6; 24.2; 29.1; 32.2; 43.8; 52.0; 52.6; 58.4; 95.9; 108.2; 117.7; 
120.1; 120.8; 124.4; 125.7; 130.6; 148.4; 151.1; 158.5; 159.5; 
160.3; 160.8; 168.1; 189.6. MS, found: m/z 488.2656 [M + H]+, 
calculated for C28H33N5O3: 488.2658. 
3-[4-Methyl-2-(morpholin-4-yl)pyrimidine-5-carbonyl]-
6,8,8,9-tetramethyl-8,9-dihydro-2H-pyranо[3,2-g]quinolin-2-
one (4с). The yield was 0.73 g (79%), m.p. 227—228 С. 1H NMR, 
: 1.36 (s, 6 H, С(8)(СН3)2); 1.93 (s, 3 Н, C(6)СН3); 2.42 (s, 3 H, 
N(9)CH3); 2.91 (s, 3 Н, C(4´)СН3); 3.65 (t, 4 Н, 2 NCH2CH2O, 
J = 5.1 Hz); 3.81 (t, 4 Н, 2 NCH2CH2O, J = 5.1 Hz); 5.49 
(s, 1 H, H(7)); 6.42 (s, 1 H, H(10)); 7.40 (s, 1 H, H(5)); 8.28 
(s, 1 H, H(4)); 8.43 (s, 1 H, H(2´)). 13C NMR, : 18.8; 24.2; 29.1; 
32.3; 44.2; 58.5; 66.4; 95.9; 108.2; 117.5; 119.7; 121.2; 124.5; 
125.3; 130.6; 148.6; 151.1; 158.6; 159.6; 160.4; 160.6; 168.0; 




The yield was 0.65 g (72%), m.p. 191—192 С. 1H NMR, : 1.26 
(s, 3 H, С(8)СН3); 1.28—1.32 (m, 6 Н, C(6)СН3, С(8)СН3); 
1.40 (t, 1 Н, Н(7), J = 13.0 Hz); 1.88 (dd, 1 Н, Н(7), J = 13.0 Hz, 
J = 3.9 Hz); 2.52 (s, 3 H, N(9)CH3); 2.77 (m, 1 Н, Н(6)); 2.93 
(s, 3 Н, C(4´)СН3); 6.47 (s, 1 H, H(10)); 7.51—7.57 (m, 4 Н, 
Ph); 8.42—8.44 (m, 2 Н, p-HPh, H(5)); 8.56 (s, 1 H, H(4)); 8.79 
(s, 1 H, H(2´)). 13C NMR, : 19.3; 23.1; 25.5; 26.6; 28.9; 32.9; 
45.1; 56.6; 96.5; 108.2; 114.8; 127.3; 128.4; 129.2; 131.7; 132.1; 
137.1; 149.9; 153.1; 156.4; 158.0; 159.8; 163.1; 164.7; 190.5. MS, 




in-2-one (5b). The yield was 0.80 g (90%), m.p. 141—145 С. 
1H NMR, : 1.25 (s, 3 H, С(8)СН3); 1.28—1.32 (m, 6 Н, C(6)СН3, 
С(8)СН3); 1.40 (t, 1 Н, Н(7), J = 13.1 Hz); 1.88 (dd, 1 Н, Н(7), 
J = 13.1 Hz, J = 4.0 Hz); 1.91—1.94 (m, 4 Н, 2 NCH2CH2 of 
pyrrolidine); 2.42 (s, 3 H, N(9)CH3); 2.78 (m, 1 Н, Н(6)); 2.91 
(s, 3 Н, C(4´)СН3); 3.54 (br.s, 4 Н, 2 NCH2 of pyrrolidine); 
6.45 (s, 1 H, H(10)); 7.48 (s, 1 H, H(5)); 8.26 (s, 1 H, H(4)); 
8.37 (s, 1 H, H(2´)). 13C NMR, : 19.4; 24.2; 25.3; 25.5; 26.7; 
29.0; 32.7; 45.4; 47.0; 56.2; 96.5; 107.8; 117.8; 120.4; 126.4; 
126.9; 148.3; 152.0; 157.1; 159.3; 159.8; 160.7; 160.9; 190.0. MS, 




in-2-one (5c). The yield was 0.70 g (76%), m.p. 165—170 С. 
1H NMR, : 1.25 (s, 3 H, С(8)СН3); 1.29—1.33 (m, 6 Н, C(6)СН3, 
С(8)СН3); 1.40 (t, 1 Н, Н(7), J = 13.2 Hz); 1.49—1.56 (m, 4 Н, 
2 NCH2CH2 of piperidine); 1.61—1.68 (m, 2 Н, NCH2CH2CH2 
of piperidine); 1.87 (dd, 1 Н, Н(7), J = 13.2 Hz, J = 4.0 Hz); 
2.41 (s, 3 H, N(9)CH3); 2.78 (m, 1 Н, Н(6)); 2.91 (s, 3 Н, 
C(4´)СН3); 3.71—3.77 (m, 4 Н, 2 NCH2 of piperidine); 6.45 
(s, 1 H, H(10)); 7.48 (s, 1 H, H(5)); 8.27 (s, 1 H, H(4)); 8.37 
(s, 1 H, H(2´)). 13C NMR, : 19.4; 24.3; 24.6; 25.5; 25.9; 26.7; 29.0; 
32.7; 44.6; 45.4; 56.2; 96.5; 107.7; 117.7; 120.3; 126.4; 127.1; 
148.4; 152.0; 157.1; 159.8; 160.2; 160.9; 168.1; 189.7. MS, found: 
m/z 461.2546 [M + H]+, calculated for C27H32N4O3: 461.2549. 
3-[2-(4-Ethylpiperazin-1-yl)-4-methylpyrimidine-5-carb-
onyl]-6,8,8,9-tetramethyl-6,7,8,9-tetrahydro-2H-pyranо [3,2-g]-
quin olin-2-one (5d). The yield was 0.87 g (89%), m.p. 199—
200 С. 1H NMR, : 1.01 (t, 3 Н, СН2СН3, J = 14.4 Hz); 1.24 
(s, 3 H, С(8)СН3); 1.29—1.32 (m, 6 Н, C(6)СН3, С(8)СН3); 
1.39 (t, 1 Н, Н(7), J = 13.1 Hz); 1.87 (dd, 1 Н, Н(7), J = 13.1 Hz, 
J = 4.0 Hz); 2.34 (q, 2 Н, СН2СН3, J = 14.4 Hz); 2.39—2.41 
(m, 7 H, 2 NCH2CH2NH, N(9)CH3); 2.77 (m, 1 Н, Н(6)); 2.91 
(s, 3 Н, C(4´)СН3); 3.81 (br.s, 4 Н, 2 NCH2CH2NH); 6.44 
(s, 1 H, H(10)); 7.47 (s, 1 H, H(5)); 8.27 (s, 1 H, H(4)); 8.37 
(s, 1 H, H(2´)). 13C NMR, : 12.4; 19.4; 24.1; 25.5; 26.7; 28.9; 
32.7; 43.8; 45.4; 52.0; 52.6; 56.2; 96.5; 107.8; 117.5; 121.0; 126.5; 
126.9; 148.5; 152.1; 157.2; 159.8; 160.4; 160.6; 168.0; 189.8. MS, 




in-2-one (5e). The yield was 0.86 g (93%), m.p. 208—210 С. 
1H NMR, : 1.25 (s, 3 H, С(8)СН3); 1.28—1.32 (m, 6 Н, C(6)СН3, 
С(8)СН3); 1.41 (t, 1 Н, Н(7), J = 13.0 Hz); 1.88 (dd, 1 Н, Н(7), 
J = 13.0 Hz, J = 4.0 Hz); 2.41 (s, 3 H, N(9)CH3); 2.78 (m, 1 Н, 
Н(6)); 2.92 (s, 3 Н, C(4´)СН3); 3.65 (t, 4 Н, 2 NCH2CH2O, 
J = 4.9 Hz); 3.80 (t, 4 Н, 2 NCH2CH2O, J = 4.9 Hz); 6.42 
(s, 1 H, H(10)); 7.49 (s, 1 H, H(5)); 8.30 (s, 1 H, H(4)); 8.41 
(s, 1 H, H(2´)). 13C NMR, : 19.4; 24.1; 25.5; 26.7; 29.0; 32.7; 44.2; 
45.3; 56.2; 66.4; 96.5; 107.9; 117.3; 121.4; 126.5; 126.9; 148.7; 
152.2; 157.2; 159.8; 160.4; 167.9; 189.8. MS, found: m/z 463.2343 
[M + H]+, calculated for C26H30N4O4: 463.2341. 
3-[2-[(4-Methylpyrimidine-2-yl)thio]acetyl]-6,8,8,9-tetra-
methyl-8,9-dihydro-2H-pyranо[3,2-g]quinolin-2-one (7a). The 
yield was 0.71 g (84%), m.p. 173—175  С. 1H NMR, : 1.37 
(s, 6 H, С(8)(СН3)2); 1.92 (s, 3 Н, C(6)СН3); 2.31 (s, 3 H, 
N(9)CH3); 2.93 (s, 3 Н, C(4´)СН3); 4.65 (s, 2 Н, СН2); 5.50 
(s, 1 H, H(7)); 6.43 (s, 1 H, H(10)); 7.03 (d, 1 Н, Н(6´), 
J = 5.1 Hz); 7.43 (s, 1 H, H(5)); 8.40 (d, 1 Н, Н(5´), J = 5.1 Hz); 
8.50 (s, 1 H, H(4)). 13C NMR, : 18.6; 23.9; 29.2; 32.4; 41.4; 
58.8; 95.6; 108.2; 114.4; 117.1; 120.3; 125.5; 130.7; 148.6; 151.7; 
155.9; 157.5; 159.1; 160.3; 167.8; 170.4; 190.7. MS, found: m/z 
422.1534 [M + H]+, calculated for C23H23N3O3S: 422.1534. 
3-[2-[(4-Methyl-4H-1,2,4-triazol-3-yl)thio]acetyl]-6,8,8,9-
tetramethyl-8,9-dihydro-2H-pyranо[3,2-g]quinolin-2-one (7b). 
The yield was 0.67 g (82%), m.p. 238—240 С. 1H NMR, : 1.37 
(s, 6 H, С(8)(СН3)2); 1.93 (s, 3 Н, C(6)СН3); 2.94 (s, 3 H, 
NCH3); 3.58 (s, 3 Н, N(4´)СН3); 4.64 (s, 2 Н, СН2); 5.51 
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(s, 1 H, H(7)); 6.43 (s, 1 H, H(10)); 7.43 (s, 1 H, H(5)); 
8.51 (s, 1 H, H(5´)); 8.52 (s, 1 H, H(4)). 13C NMR, : 18.6; 
29.2; 31.2; 32.5; 44.7; 58.9; 95.6; 108.3; 113.3; 120.4; 125.1; 
130.8; 146.6; 148.9; 149.1; 149.2; 151.9; 159.3; 160.2; 189.9. MS, 




The yield was 0.67 g (79%), m.p. 167—168 С. 1H NMR, : 1.25 
(s, 3 H, С(8)СН3); 1.29 (d, 3 Н, C(6)СН3, J = 6.6 Hz); 1.31 
(s, 3 H, С(8)СН3); 1.40 (t, 1 Н, Н(7), J = 13.1 Hz); 1.87 (dd, 1 Н, 
Н(7), J = 13.1 Hz, J = 3.9 Hz); 2.31 (s, 3 H, N(9)CH3); 2.78 
(m, 1 Н, Н(6)); 4.65 (s, 2 Н, СН2); 6.46 (s, 1 H, H(10)); 7.03 
(d, 1 Н, Н(6´), J = 5.1 Hz); 7.52 (s, 1 H, H(5)); 8.39 (d, 1 Н, 
Н(5´), J = 5.1 Hz); 8.52 (s, 1 H, H(4)). 13C NMR, : 19.3; 23.9; 
25.5; 28.9; 32.8; 41.4; 45.1; 56.5; 96.2; 107.9; 114.2; 117.1; 127.1; 
127.3; 148.7; 152.8; 157.5; 157.7; 150.5; 167.8; 170.4; 190.8. MS, 




(8b). The yield was 0.66 g (80%), m.p. 209—211 С. 1H NMR, 
: 1.26 (s, 3 H, С(8)СН3); 1.28—1.32 (m, 6 Н, C(6)СН3, 
С(8)СН3); 1.40 (t, 1 Н, Н(7), J = 13.2 Hz); 1.87 (dd, 1 Н, Н(7), 
J = 13.2 Hz, J = 4.0 Hz); 2.76 (m, 1 Н, Н(6)); 2.93 (s, 3 H, 
N(9)CH3); 3.58 (s, 3 Н, N(4´)СН3); 4.64 (s, 2 Н, СН2); 6.45 
(s, 1 H, H(10)); 7.51 (s, 1 H, H(5)); 8.51 (s, 1 H, H(5´)); 8.53 
(s, 1 H, H(4)). 13C NMR, : 19.3; 25.5; 26.6; 28.9; 31.2; 32.9; 
44.6; 45.0; 56.6; 96.2; 108.0; 113.0; 127.2; 127.4; 146.5; 149.0; 
149.2; 153.1; 157.8; 160.5; 190.0. MS, found: m/z 413.1641 
[M + H]+, calculated for C21H24N4O3S: 413.1643. 
Inhibitory activity of compounds 4a—с, 5а—е, 7a,b, and 8a,b 
against blood coagulation factors Ха and XIa. The inhibition of 
blood clotting factors Xa and XIa by the synthesized compounds 
was studied by measuring the kinetics of hydrolysis of substrates 
specifi c for each of these enzymes in the presence of these com-
pounds. A specifi c low-molecular-weight chromogenic substrate 
S2765 (Z-D-Arg-Gly-Arg-pNA•2HCl) was used in the case of 
factor Xa, while the substrate S2366 (pyroGlu-Pro-ArgpNA•HCl) 
(both from Chromogenix, USA) was used for factor XIa.
A buff er containing 140 mМ NaCl, 20 mМ HEPES, and 0.1% 
PEG 6000 (рН 8.0) was placed in the wells of a 96-well plate, 
followed by the addition of factor Ха (fi nal concentration 
2.5 nmol  L–1) or XIa (fi nal concentration 0.8 nmol  L–1), the 
substrate S2765 (fi nal concentration 200 μmol  L–1) or S2366 
(fi nal concentration 200 μmol  L–1), and a solution of the 
test compound in DMSO (fi nal concentration 30 μmol  L–1, 
the DMSO content in the well was no more than 2%). The kinet-
ics of the formation of 4-nitroaniline was measured using 
a THERMOmax Microplate Reader (Molecular Devices Cor-
poration, USA) by the absorption of light with a wavelength of 
405 nm. The initial rate of substrate degradation was determined 
from the initial slope of the 4-nitroaniline formation curve. The 
rate of substrate degradation by the enzyme in the presence of 
the inhibitor was expressed as a percentage relative to the rate of 
substrate degradation in the absence of the inhibitor. The results 
are presented in Table 1. The data obtained were processed using 
the GraphPad Prism and OriginPro 8 software. 
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